Table 2.
The annual risks of thromboembolism (ischemic stroke, peripheral embolism, or pulmonary embolism) for CHA2DS2-VASc, adjusted for aspirin use [12]
| CHA2DS2-VASc score | Risk (events/persons) |
|---|---|
| 0 | 0 (0/103) |
| 1 | 0.7 (1/162) |
| 2 | 1.9 (3/184) |
| 3 | 4.7 (8/203) |
| 4 | 2.3 (4/208) |
| 5 | 3.9 (3/95) |
| 6 | 4.5 (2/57) |
| 7 | 10.1 (2/25) |
| 8 | 14.2 (1/9) |
| 9 | 100 (1/1) |
The original study deriving the CHA2DS2-VASc consisting of 1084 AF patients with a follow-up of 1 year, considering ischemic stroke, peripheral embolism, or pulmonary embolism as outcomes for thromboembolism